{"id":"mrg002","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MRG002 functions as a bispecific antibody designed to bridge tumor cells and immune cells, typically by binding to a tumor-associated antigen on one arm and an immune checkpoint or activating receptor on the other. This dual engagement aims to redirect and amplify immune cell killing of cancer cells while potentially overcoming immune evasion mechanisms.","oneSentence":"MRG002 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:13.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT06869174","phase":"PHASE2","title":"Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary","status":"NOT_YET_RECRUITING","sponsor":"Zhiguo Luo, MD, PhD","startDate":"2025-03-08","conditions":"Cancer of Unknown Primary","enrollment":50},{"nctId":"NCT04492488","phase":"PHASE1, PHASE2","title":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-05-24","conditions":"Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer","enrollment":129},{"nctId":"NCT05754853","phase":"PHASE3","title":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2023-04-06","conditions":"Advanced or Metastatic Urothelium Cancer","enrollment":290},{"nctId":"NCT04924699","phase":"PHASE2, PHASE3","title":"A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-06-30","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":350},{"nctId":"NCT05263869","phase":"PHASE2","title":"A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2022-03-23","conditions":"Breast Cancer With Liver Metastases","enrollment":99},{"nctId":"NCT05338957","phase":"PHASE1, PHASE2","title":"A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2022-08-05","conditions":"Advanced Malignant Solid Tumors","enrollment":30},{"nctId":"NCT04742153","phase":"PHASE2","title":"A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-05-13","conditions":"Advanced or Metastatic Breast Cancer","enrollment":66},{"nctId":"NCT05141747","phase":"PHASE2","title":"A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2022-01-19","conditions":"Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer","enrollment":60},{"nctId":"NCT04839510","phase":"PHASE2","title":"A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-04-20","conditions":"Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma","enrollment":58},{"nctId":"NCT04837508","phase":"PHASE2","title":"A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-06-07","conditions":"Advanced or Metastatic Biliary Tract Cancer","enrollment":86},{"nctId":"NCT04941339","phase":"PHASE1","title":"A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2018-11-21","conditions":"Advanced Solid Tumor","enrollment":74},{"nctId":"NCT05141786","phase":"PHASE2","title":"A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-12","conditions":"Non-small- Cell Lung Cancer (NSCLC)","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MRG002","genericName":"MRG002","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MRG002 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity. Used for Solid tumors (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}